Every 424B that IDEAYA Biosciences, Inc. (IDYA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow IDYA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IDYA filings page.
IDEAYA Biosciences is offering 5,555,556 shares of common stock and pre-funded warrants to purchase 5,555,576 shares of common stock. The public offering price is $27.00 per share and $26.9999 per pre-funded warrant, with estimated net proceeds of approximately $281.3 million before expenses. The underwriters have a 30-day option to purchase up to 1,666,669 additional shares. The prospectus supplement states proceeds are intended to fund continued clinical development and potential commercialization of darovasertib, advancement of the company’s pipeline and general corporate purposes.
IDEAYA Biosciences, Inc. is offering $300,000,000 of common stock and, in lieu of shares to certain investors, pre-funded warrants exercisable at $0.0001 per share, with an underwriter option to purchase an additional $45,000,000 of common stock.
The prospectus supplement is part of a shelf registration and ties the offering to proceeds intended for continued clinical development and potential commercialization of darovasertib, advancement of the company’s precision oncology pipeline, and general corporate purposes. The document discloses 87,856,154 shares outstanding as of March 31, 2026 and reports a historical net tangible book value of $937.3 million (or $10.67 per share) as of that date.
IDEAYA Biosciences filed a prospectus supplement for an at-the-market offering under a shelf registration that permits up to $350,000,000 aggregate sales of common stock through Jefferies LLC as sales agent. The supplement states $193,447,003.19 of that capacity has been sold previously and $156,552,996.81 remains available for sale under the January 19, 2024 sales agreement. Sales will be made on Nasdaq as “at the market offerings” and Jefferies may receive up to 3.0% of gross proceeds as compensation. The filing discloses 87,856,154 shares outstanding as of March 31, 2026 and a last reported sales price of $28.19 per share on May 1, 2026. The company intends to use net proceeds for general corporate purposes, including working capital and clinical development.